Fate Therapeutics, Inc. (FATE)
1.375
-0.02
(-1.79%)
USD |
NASDAQ |
Feb 20, 11:45
Fate Therapeutics EPS Diluted (Quarterly) : -0.271 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| MannKind Corp. | 0.0256 |
| Vertex Pharmaceuticals, Inc. | 4.651 |
| Ardelyx, Inc. | -0.004 |
| ACADIA Pharmaceuticals, Inc. | 0.4206 |
| Alnylam Pharmaceuticals, Inc. | 1.368 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -32.25M |
| Revenue (Quarterly) | 1.741M |
| Total Expenses (Quarterly) | 33.99M |
| Enterprise Value | 25.32M |
| Gross Profit Margin (Quarterly) | -85.35% |
| Profit Margin (Quarterly) | -1.85K% |
| Earnings Yield | -95.93% |
| Normalized Earnings Yield | -89.90 |